Evidence map›Paper›PMID 40162352›Full record

ArticleIndian journal of dermatology

Assessment of Systemic Oxidative Stress Modulation in Melasma Following Treatment with Yellow Light Laser 577 nm and Topical 0.3% 4N Butyl Resorcinol: A Comparative Prospective Study.

Neelam Khurana, Mohammad M Mehdi, Mohinder P S Sawhney, Sanjiv K Bansal

Abstract read
In one paragraph

Article in Indian journal of dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Neelam KhuranaFrom the Department of Biosciences and Bioengineering, Lovely Professional University, Phagwara, Punjab, India.
Mohammad M MehdiFrom the Department of Biosciences and Bioengineering, Lovely Professional University, Phagwara, Punjab, India.
Mohinder P S SawhneyDepartment of Dermatology and STD, FMHS, SGT University, Chandu-Budhera, Gurugram, Haryana, India.
Sanjiv K BansalDepartment of Biochemistry, FMHS, SGT University, Chandu-Budhera, Gurugram, Haryana, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Melasma is an acquired hyperpigmentation disorder of the skin. Recent studies suggest that oxidative stress may contribute to the pathogenesis of melasma. Upregulated levels of circulatory antioxidants in blood serum and vascular endothelial growth factors in melasma lesions have been observed. The prospective study was conducted to compare the effect of the treatment of melasma with and without the use of a 577 nm vascular laser on levels of enzymatic antioxidants. Aims and Objectives: To compare the modulation in the levels of enzymatic antioxidants in melasma patients treated with 577 nm yellow light laser in combination with topical depigmenting serum as compared to those using depigmenting serum alone. Materials and Methods: Sixty patients with melasma of both sexes were randomly divided into groups of 30 each. Group A patients were treated with yellow light laser 577 nm (wavelength) once every 4 weeks for 4 sittings and topical depigmenting serum (4n butyl resorcinol) daily for 24 weeks. Group B patients were treated only with topical depigmenting serum. Levels of total antioxidant capacity (TAC), superoxide dismutase (SOD), inducible nitric oxide synthase (iNOS), glutathione peroxidase (GPx) and malondialdehydes (MDA) were estimated at 0 and 24 weeks. Results: Mean difference in lowering of the antioxidant levels in Group A and B was SOD1 (0.73 versus 0.12), GPX1, (0.62 versus 0.30), iNOS (1.56 versus 0.52), MDA, (0.73 versus 0.38), TAC (2.24 versus 1.28). A significantly higher mean of difference was observed in patients treated with combination therapy. Conclusion: Significantly higher reduction of enzymatic antioxidants with 577 nm yellow light laser in combination with 4 N-butyl resorcinol as compared to topical depigmenting agent alone recommends that combination therapy in melasma may target different aspects of a condition to enhance overall effectiveness.

Indexed as

4N butyl resorcinolglutathione peroxidase (GPx)inducible nitric oxide synthase (iNOS)malondialdehydes (MDA)melasmasuperoxide dismutase (SOD)total antioxidant capacity (TAC)yellow light laser 577 nm

Identifiers

PMID40162352
PMCPMC11952710

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.